Historical information, Holdings LP.. Transfersome called Innovative drug carriers developed for the noninvasive delivery of agents into or through the skin. Transfersome preparations consist of complex lipid vesicles the skin the skin permeability barrier, the stratum, the water gradient driven transcutaneous intersect. TDT 067 is a novel, epicutaneously applied carrier-based dosage form of terbinafine for the treatment of onychomycosis of the toenail and fingernail. Celtic Pharma acquired an exclusive worldwide license for Transfersome technology IDEA in February 2006. ‘ Transfersome is a registered trademark of IDEA.
The disease has a high incidence in the general population – estimated as high as 13 percent in the U.S. – especially in the elderly, with only a small %age of patients who are treated. Current treatment options include both oral and topical medications are oral treatments with better results. Er, these oral therapies remains a black box warning and carry the risk of systemic side effects, especially hepatoxicity. Disproportionate to the disease, which can be treated This results in a large %age of the condition is not affected, the most effective treatments given.. Dr. Bardur Sigurgeirsson, Department of Dermatology, University of Iceland, the Principal Investigator for Europe added: I am delighted to study study of this innovative new product, which I believe is an important advance in the therapy, area. Continue reading